ORY — ORYZON Genomics SA Share News
0.000.00%
Last trade - 00:00- €204.89m
- €196.06m
Spanish stocks - Factors to watch on Sept 23
Brief: Oryzon Presents Final Data From Vafidemstat’s Phase IIb Portico Trial In Borderline Personality Disorder
Spanish stocks - Factors to watch on Sept 12
Brief: Oryzon Receives “Intention To Grant” Communication For Patent Relating To Use Of Vafidemstat In Borderline Personality Disorder
Brief: Oryzon Gets "Intention To Grant" Communication For Patent Regarding vafidemstat
Europe Research Roundup: Elis, Spie, Volvo
Brief: Oryzon Says Nice & Green Requests Bonds Conversion For 880,000 Euros
Brief: Oryzon H1 Net Loss Widens To 1.0 Mln Euros YoY
Brief: Oryzon Says Investor To Convert Bonds For Nominal Amount Of 270,000 Euros
Brief: Oryzon Receives "Decision To Grant" For Two Important Patents For Vafidemstat In Japan
Spanish stocks - Factors to watch on July 8
Brief: Oryzon Gets "Decision To Grant" For Two Vafidemstat Patents In Japan
Brief: Oryzon Says Nice & Green Requests Bonds Conversion For 1.1 Mln Euros
Brief: Oryzon Approves Resolution To Increase Capital For Up To 100 Mln Euros
Refile: BRIEF-Oryzon Says Nice & Green Applies Conversion Of Bonds For 570,000 Euros
Brief: Oryzon Says Nice & Green Applies For Conversion Of Bonds For 480,000 Euros
Brief: Oryzon Says Nice & Green Applies For Conversion Of Bonds For 660,000 Euros
Brief: Oryzon Presents Preliminary Data From Ongoing Phase Ib Frida Trial
Brief: Oryzon Presents Promising Preliminary Results from Phase IB FRIDA Trial at EHA-2024